drugset
Drugs / glycopyrrolate/formoterol fumarate
last change Jul 2017 re-read 2 minutes ago

glycopyrrolate/formoterol fumarate

also known as glycopyrrolate/formoterol fumarate metered-dose inhaler
Developed for
chronic obstructive pulmonary disease
Investigated by
Pearl Therapeutics, Inc.

Trials 1 · a red edge is where a trial was stopped

today NCT01854658 · Ph 3
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01854658 Jul 2013 → Mar 2015 chronic obstructive pulmonary disease Pearl Therapeutics, Inc. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as glycopyrrolate/formoterol fumarate “The clinical severity of COPD is currently categorized by symptom burden and exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that...” PMID 28720336 ↗ Jul 2017
Known as glycopyrrolate/formoterol fumarate metered-dose inhaler “glycopyrrolate/formoterol fumarate metered-dose inhaler” NCT01854658 ↗
Route Inhaled “glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI)” NCT01854658 ↗